ADC Therapeutics SA
NYSE:ADCT

Watchlist Manager
ADC Therapeutics SA Logo
ADC Therapeutics SA
NYSE:ADCT
Watchlist
Price: 1.83 USD 4.57% Market Closed
Market Cap: 176.9m USD

Net Margin
ADC Therapeutics SA

-297.3%
Current
-339%
Average
-7.9%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-297.3%
=
Net Income
-367.2m
/
Revenue
123.5m

Net Margin Across Competitors

Country Company Market Cap Net
Margin
CH
ADC Therapeutics SA
NYSE:ADCT
176.9m USD
-297%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-21 040%
US
Abbvie Inc
NYSE:ABBV
303.2B USD
9%
US
Amgen Inc
NASDAQ:AMGN
146.3B USD
13%
US
Gilead Sciences Inc
NASDAQ:GILD
114.4B USD
0%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
108.8B USD
-5%
US
Epizyme Inc
F:EPE
94.1B EUR
-392%
AU
CSL Ltd
ASX:CSL
132.7B AUD
18%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
75B USD
34%
US
Seagen Inc
F:SGT
39.3B EUR
-33%
NL
argenx SE
XBRU:ARGX
38.1B EUR
-5%

ADC Therapeutics SA
Glance View

Market Cap
176.9m USD
Industry
Biotechnology

ADC Therapeutics SA is a clinical-stage biotechnology company. The company is headquartered in Epalinges, Vaud and currently employs 312 full-time employees. The company develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. The company employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The firm has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkin’s lymphoma and B-cell leukemia. The company serves customers in the United States, Switzerland, and the United Kingdom.

ADCT Intrinsic Value
4.91 USD
Undervaluation 63%
Intrinsic Value
Price
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-297.3%
=
Net Income
-367.2m
/
Revenue
123.5m
What is the Net Margin of ADC Therapeutics SA?

Based on ADC Therapeutics SA's most recent financial statements, the company has Net Margin of -297.3%.

Back to Top